Overcoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin/OKI-179 to promote apoptosis

• Published in: Breast cancer research : BCR Vol. 26; no. 1; p. 35
• Main Authors: Smoots, Stephen G, Schreiber, Anna R, Jackson, Marilyn M, Bagby, Stacey M, Dominguez, Adrian T A, Dus, Evan D, Binns, Cameron A, MacBeth, Morgan, Whitty, Phaedra A, Diamond, Jennifer R, Pitts, Todd M
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 01.03.2024; BioMed Central; BMC
• Subjects: Annexin V; Apoptosis; Autophagy; Bioavailability; Biotechnology industry; Breast cancer; Cancer; Cancer therapies; Cell cycle; Cell division; Cell fate; Chemoresistance; Chemotherapy; DNA damage; DNA repair; Doxorubicin; Flow cytometry; Genes; Growth inhibition; Histone deacetylase; Histone deacetylase inhibitor; Immunoblotting; Kinases; Mutation; Prognosis; Proteins; Senescence; Toxicity; Triple-negative breast cancer; Tumor proteins; Tumors; β-Galactosidase; United States; United States > US; Doxorubicin; Histone deacetylase inhibitor; Triple-negative breast cancer
• ISSN: 1465-542X; 1465-5411; 1465-542X
• DOI: 10.1186/s13058-024-01799-5

Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype with a poor prognosis. Doxorubicin is part of standard curative therapy for TNBC, but chemotherapy resistance remains an important clinical challenge. Bocodepsin (OKI-179) is a small molecule class I histone deacetylase (HDAC) inhibitor that promotes apoptosis in TNBC preclinical models. The purpose of this study was to investigate the combination of bocodepsin and doxorubicin in preclinical TNBC models and evaluate the impact on terminal cell fate, including apoptosis and senescence. TNBC cell lines were treated with doxorubicin and CellTiter-Glo was used to assess proliferation and determine doxorubicin sensitivity. Select cell lines were treated with OKI-005 (in vitro version of bocodepsin) and doxorubicin and assessed for proliferation, apoptosis as measured by Annexin V/PI, and cell cycle by flow cytometry. Immunoblotting was used to assess changes in mediators of apoptosis, cell cycle arrest, and senescence. Senescence was measured by the senescence-associated β-galactosidase assay. An MDA-MB-231 xenograft in vivo model was treated with bocodepsin, doxorubicin, or the combination and assessed for inhibition of tumor growth. shRNA knockdown of p53 was performed in the CAL-51 cell line and proliferation, apoptosis and senescence were assessed in response to combination treatment. OKI-005 and doxorubicin resulted in synergistic antiproliferative activity in TNBC cells lines regardless of p53 mutation status. The combination led to increased apoptosis and decreased senescence. In vivo, the combination resulted in increased tumor growth inhibition compared to either single agent. shRNA knock-down of p53 led to increased doxorubicin-induced senescence that was decreased with the addition of OKI-005 in vitro. The addition of bocodepsin to doxorubicin resulted in synergistic antiproliferative activity in vitro, improved tumor growth inhibition in vivo, and promotion of apoptosis which makes this a promising combination to overcome doxorubicin resistance in TNBC. Bocodepsin is currently in clinical development and has a favorable toxicity profile compared to other HDAC inhibitors supporting the feasibility of evaluating this combination in patients with TNBC.